相关实验视频

Updated: Jun 23, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

史基索体中的实质量子抗性:简要报告

Gabriela Eastham¹, Dane Fausnacht², Matthew H Becker¹

¹Department of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA, United States.

Frontiers in parasitology

|January 16, 2025

概括

普拉西量子特 (PZQ) 是治疗疹的主要治疗方法,但对寄生虫耐药性的担忧越来越大,需要探索替代疗法. 本综述审查了支持和反对PZQ耐药性的证据,并讨论了未来的治疗策略.

科学领域:

被忽视的热带疾病被忽视的热带疾病
寄生虫学的寄生虫学
药物耐药性研究的研究.

背景情况:

全球有超过1.4亿人患有istosomiasis,由*Schistosoma*属的寄生性三角虫引起.
由于研究和治疗选择有限,它被归类为被忽视的热带疾病.
目前的治疗方法对早期感染无效,后期感染的主要药物是praziquantel (PZQ).

研究的目的:

审查现有的关于虫虫 (PZQ) 耐药性的文献.
探索基因组研究,建议的耐药性机制,以及对杆菌病的替代治疗策略.
评估证据支持对PZQ耐药性的担忧.

主要方法:

科学文章的文献综述关于疹和PZQ的科学文章.
分析与 * Schistosoma * 耐药性相关的基因组数据.
综合关于拟议的抗药性机制和替代治疗方法的信息.

主要成果:

PZQ对所有三种主要的 * Schistosoma * 物种都有效,但由于大规模的药物管理计划,人们对耐药性的担忧正在增加.
目前正在评估支持和反对PZQ耐药性的证据,以及基因组研究和拟议的耐药性机制.
目前还没有有效的治疗方法来治疗早期的阴茎杆菌病,阴茎杆菌性皮炎或卡塔亚马综合征.

结论:

由于人们越来越多地依赖PZQ来治疗杆菌病,因此需要对潜在的寄生虫耐药性进行彻底调查.
鉴于对PZQ的局限性和潜在耐药性,对替代性杆菌病治疗的进一步研究至关重要.
了解PZQ耐药机制和探索新的治疗途径对于对抗这种被忽视的热带疾病至关重要.

关键词:

有效性有效性有效性.大规模的药物管理.在Praziquantel中使用.电阻的电阻是指电阻的电阻这种疾病叫做schistosomiasis.

更多相关视频

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum

Published on: December 4, 2015

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

相关概念视频

Malaria

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...